INTRODUCTION
More than 1 million individuals in the USA and over 40 million people worldwide are infected with the HIV. Combination antiretroviral treatment (cART) has transformed HIV from a rapidly fatal disease to a more manageable chronic condition [1] [2] [3] . As a result, HIV-infected (HIVþ) individuals receiving cART have almost as long a lifespan as HIV-uninfected (HIV-) individuals [4] . A majority of HIVþ patients will be greater than 50 years old by 2015 [5] .
Despite these advances, HIV cannot be eradicated from the brain with persistent reservoirs often remaining [6 & ]. The continued presence of HIVassociated neurocognitive disorders (HAND) despite cART could result from nonmutually exclusive factors, including irreversible injury prior to initiating cART, persistent HIV-1 RNA in the brain [7] , antiretroviral treatment toxicities [8] [9] [10] , and/or persistent low-level inflammation [11] . Currently, the diagnosis of HAND requires neuropsychological performance testing and self-reported assessment of activities of daily living with the following classifications used: neuropsychologically normal, asymptomatic neurocognitive impairment, mild neurocognitive disorder, or HIV-associated dementia (HAD) [12] . Compared to other neurodegenerative disorders (e.g., Alzheimer's disease), additional biomarkers have yet to be added to HAND research criteria.
Neuroimaging could have increased utility in the diagnosis and management of HAND. A variety of novel neuroimaging techniques have been developed and are currently performed in the research setting. Of note, MRI techniques [including magnetic resonance spectroscopy (MRS), volumetrics, diffusion tensor imaging (DTI), and functional] and PET have been utilized in HIVþ individuals. This review is not meant to be comprehensive. Instead, it briefly discusses recent results (within the past 3 years) using some of these neuroimaging methods.
MAGNETIC RESONANCE SPECTROSCOPY
The most common neuroimaging method for studying neuroHIV in the precART and postcART eras has been MRS [13] [14] [15] [16] . MRS detects the signal produced by protons of specific molecules within a volume of brain. Molecules that are typically measured include: first, N-acetyl-aspartate -a neuronal marker; second, choline -a marker of cellular proliferation and inflammatory response; third, creatine -a measure of brain energy metabolism and reference marker; and fourth, myoinositol -a marker of gliosis. MRS can provide key insights into longitudinal changes in brain metabolites as an individual progresses from primary (1 year since seroconversion) to chronic (>1 year since seroconversion) infection. Soon after seroconversion, MRS metabolites are affected [14, [17] [18] [19] with observed neuroimaging changes correlating with inflammation [17] and neuronal injury [19] . Changes seen due to HIV are often observed within both subcortical (basal ganglia) and cortical (frontal grey/white matter and parietal grey matter) compared with HIV-controls. HIVþ patients with chronic infection have reduced N-acetyl-aspartate and concomitant increased choline and myo-inositol [15, [20] [21] [22] [23] . MRS metabolite changes in chronically infected HIVþ patients vary according to HAND status with HAD patients showing the greatest changes [15, 21] .
cART can lead to significant improvements, but not normalization of MRS metabolite levels [23] [24] [25] . Early treatment with cART may be neuroprotective and mitigate some of the changes seen soon after seroconversion. However, certain antiretrovirals may cause mitochondrial toxicity and impair neuronal function [9, 26] .
HIVþ patients are living longer and growing older due to cART. A number of MRS studies have, therefore, investigated the interaction between HIV and aging [27] . HIVþ patients have significant changes in brain metabolites with levels measured equivalent to those seen in HIVcontrols at least 10-15 years older [28] . In general, no interaction has been observed between HIV and aging [2] .
Overall, MRS changes may be more sensitive than conventional MRI alone in detecting changes associated with HIV. MRS could augment current neuroimaging protocols but local implementation of sequences is required. In the future, MRS could be used to evaluate the efficacy of certain therapeutics. However, most MRS studies have been crosssectional and have primarily focused on specific regions of interest. Additional longitudinal studies that focus on HIVþ patients as they transition across different disease states are needed [29] .
STRUCTURAL NEUROIMAGING-VOLUMETRICS AND DIFFUSION TENSOR IMAGING
Volumetric MRI can assess brain structural differences between HIVþ and HIV-individuals [30] . This technique can concentrate on either specific brain structures or relatively large brain areas [31] . In the precART era, significant volume loss was seen in the basal ganglia, posterior cortex, and white matter of HIVþ patients compared with HIVcontrols [32] [33] [34] . The greatest changes in volumetrics were seen in more advanced stages of HAND [35] . In the cART era, both subcortical and cortical atrophy have been observed in HIVþ patients [36] [37] [38] suggesting that brain volume loss can still occur despite the initiation of effective treatment [20, 30] . More recently, volumetric changes have been shown to correlate with the degree of cognitive impairment and virologic markers. Poorer neurocognitive performance has been associated with smaller brain volumes [22, 37, 39, 40, 41 & ,42-46] and greater viral burden. In addition, impaired immune response (nadir CD4 þ T lymphocyte counts) has been associated with greater atrophy [20, 38, 40 
KEY POINTS
The effects of HIV in the brain can be noninvasively assessed by structural (e.g., volumetrics and DTI) and functional (e.g., blood-oxygen-level-dependent imaging) MRI.
PET of glucose metabolism, neurotransmitter systems' abnormalities, or amyloid deposition could provide additional understanding of the neuropathophysiological changes associated with HIV.
Novel neuroimaging methods could be added to current criteria for defining HAND. These methods may also help in evaluating the efficacy of cART regimens.
Neuroimaging studies that are longitudinal; have larger sample sizes of both HIV infected (HIVþ) and HIV uninfected (HIV-); and include HIVþ patients of different disease durations are needed.
Diffusion tensor imaging DTI technique has become increasingly popular in the assessment of white matter structural integrity in the setting of HIV. This neuroimaging technique measures the diffusion of water molecules [45, [51] [52] [53] . In the isotropic state water motion is equal in all directions (e.g., cerebrospinal fluid). In brain tissues the movement of water is anisotropic, with diffusion greater along the length of fiber tracts compared with perpendicular to them [54] . For each voxel, a tensor is calculated that describes the three-dimensional shape of water diffusion. Fiber direction is indicated by the tensor's main eigenvector. Mean diffusivity reflects the average diffusion in three axes. Fractional anisotropy assesses the general shape of the ellipsoid [55] .
Most studies have shown that HIV leads to an increase in mean diffusivity and a decrease in fractional anisotropy within white matter tracts. However, subtle differences may exist as to where changes are observed depending on the study [56] [57] [58] 59 & ]. To date, no studies have assessed DTI changes soon after seroconversion. Typically, HIVþ individuals receiving cART (HIVþ/cARTþ) and those naïve to cART (HIVþ/cART-) have been merged and compared with HIV-controls. Conflicting results have been observed in the few studies that have investigated the impact of cART using DTI [60, 61,62 & ]. Overall, quantitative volumetric changes may be more sensitive than current conventional MRI evaluation. In the future, DTI could be used to evaluate the efficacy of certain therapeutics but additional longitudinal studies that focus on HIVþ patients soon after seroconversion are needed.
FUNCTIONAL MAGNETIC RESONANCE IMAGING
Studies are now starting to utilize blood oxygen level dependent (BOLD) functional MRI (fMRI) to investigate the effects of HIV on brain function [63] . Changes in the BOLD response for a particular stimulus can indirectly reveal the coupling between neuronal activity and cerebral blood flow within certain brain regions [64] . HIVþ patients have greater BOLD activity in the parietal lobes for a simple attention task and greater frontal and parietal activation during more complex attention tasks [65] . These BOLD changes in HIVþ patients may reflect the recruitment of surrounding areas to meet cognitive requirements [24, 28, 42, [65] [66] [67] [68] [69] [70] [71] [72] [73] . A recent systematic meta-analysis of BOLD fMRI studies using various functional tasks in HIVþ patients was recently performed using activation likelihood estimation. HIVþ patients had greater functional activation within the left inferior frontal gyrus and caudate nucleus compared with HIV-controls [74 && ]. Dysfunction in the fronto-striatal network was qualitatively related to degree of neurocognitive impairment. Differences between HIVþ and HIVindividuals can also be seen at rest using BOLD imaging. In particular, functional correlations between brain networks are significantly reduced in HIVþ patients and a signature of the disease may be present that is different than other neurodegenerative disorders. The effects of HIV and aging on BOLD resting state functional correlations were shown to be independent of each other [75 & ]. However, the effects of cART have not been assessed using BOLD imaging. Additional studies of cerebral blood flow have nicely complemented existing BOLD studies and have demonstrated a reduction in resting cerebral blood flow in HIVþ individuals compared with HIV-controls [76, 77] .
Overall, functional neuroimaging studies have been performed in a limited number of HIVþ patients. Additional longitudinal fMRI studies are needed to determine if these techniques could be used to follow HIVþ individuals. Future, BOLD studies could evaluate the efficacy of various treatment regimens for HAND.
POSITRON EMISSION TOMOGRAPHY
Fluorodeoxyglucose (FDG)-PET imaging is a commonly used technique that measures the metabolic activity of various cells/tissues, such as in neoplastic diseases. In the brain, evaluation of FDG uptake by neurons has been utilized in multiple central nervous system (CNS) disorders, such as Alzheimer's disease and Parkinson's disease [78] . In neuroHIV, early FDG-PET studies demonstrated lower cerebral metabolic rate for glucose consumption in HIVþ patients compared with age-matched HIVpatients, despite the lack of structural abnormalities on MRI [79] . This probably was the first insight into early metabolic changes can occur with HIV infection without gross structural volumetric loss. Subsequent FDG-PET studies [80] [81] [82] have described two unique metabolic signatures of glucose abnormalities associated with HIV infection. The first was a hypermetabolic state, particularly in the striatum, which appeared to provide a disease-specific measure of early CNS involvement, despite normal motor function on neuropsychological performance testing. This was assumed to reflect abnormal functional connectivity within subcortical areas [82] . A second pattern was seen during chronic stages and was characterized by generalized hypometabolism in both cortical and subcortical regions. These changes correlated with age, cerebral atrophy, and neurocognitive status [81] . A switch from the hypermetabolic to hypometabolic states in subcortical areas (e.g., basal ganglia) was associated with changes in functional deficits and progression to dementia [82] .
In the cART era, more subtle FDG-PET changes have been observed [83, 84 && ] and can still be seen in optimally treated HIVþ patients with virologic suppression. At least half of HIVþ patients on cART can have varying degrees of hypometabolism in the mesial frontal lobes [83] . These abnormalities are accentuated by drug abuse and can lead to extensive cortical hypometabolism [85] . In contrast to some MRI studies, a synergistic interaction has been observed between aging and HIV with changes primarily seen in the frontal regions [84 && ]. Ongoing CNS injury observed despite peripheral virologic suppression may reflect persistent low-level neuroinflammation. A few studies have attempted to characterize neuroinflammation using PET ligands that specifically target microglia activation. The most commonly used ligand has been 11 C-PK11195 that binds to the translocator protein (TSPO), a mitochondrial receptor known to be significantly upregulated in activated microglia [86, 87] . Early studies showed significantly higher 11 C-PK11195 binding in HAD patients compared with HIV-controls within five out of eight brain regions of interest. However within a subgroup of nondemented HIVþ patients, no significant increases in binding were seen when compared with HIV-controls [88] . A subsequent larger study using 11 C-PK11195 failed to show increases in ligand retention in the brain parenchyma of HIVþ patients compared with HIV-controls [89] . One possible explanation for observed differences could be due to the variability of the HIVþ patient populations recruited for these studies. Although Hammoud et al. [88] included cognitively impaired HIVþ who were not receiving cART, Wiley et al. [89] only evaluated cognitively normal HIVþ patients receiving treatment [89] . A subsequent study by Garvey et al. [90] compared chronically infected HIVþ patients with and without concomitant HCV infection. No significant differences were noted between these two groups. However, HIVþ/cARTþ individuals had lower ligand-binding potentials in the parietal and frontal regions than HIVþ/cARTpatients. A follow-up study by the same group compared HIVþ/cARTþ patients with HIV-controls and showed clusters of increased ligand binding within the corpus callosum, anterior and posterior cingulate gyrus, temporal gyrus, and frontal regions [91 && ].
Limitations of 11 C-PK11195, including its' high nonspecific binding and high lipophilicity, have led some to question the reliability of this ligand. Subsequent attempts have been made to use secondgeneration TSPO-PET ligands with higher specific to nonspecific binding ratios. However, these second generation agents have different binding affinities within HIV-controls. In particular, a genetic polymorphism of the TSPO receptor has been discovered and could affect the binding potential of these various ligands [92 && ,93] . This discovery has further complicated the analysis of TSPO-PET imaging as patients must be stratified as low-affinity binders, high-affinity binders, or heterozygous [92 && ]. Crosssectional comparisons, in theory, cannot be done except within the same binding affinity group. Despite these limitations, one study used a secondgeneration TSPO ligand ( 11 C-DPA713) to compare HIVþ/cARTþ individuals and HIV-controls [94 & ]. Adapting a new method of data analysis based on assessing the volume-of-distribution ratios relative to overall gray matter, HIVþ patients were noted to have higher binding in specific brain regions that may reflect localized rather than diffuse glial cell activation. A novel gray matter normalization approach was employed that improves test-retest reproducibility and may uncover abnormal regional findings not seen using traditional methods [94 & ]. However, additional studies are needed to validate this method for other TSPO ligands.
A third use of PET imaging in the setting of neuroHIV is the evaluation specific neurotransmitter systems. The first system to be evaluated was the dopaminergic system. Significantly, lower dopamine transporters (DAT) availability was seen in the putamen of HIVþ patients with HAD compared with nondemented HIVþ patients. In addition, lower DAT levels were seen in the ventral striatum of HIVþ patients when compared with HIV-patients [95] . These findings suggested dopaminergic terminal injury occurs in HIVþ patients with significant cognitive impairment. Within the HIVþ demented group, higher plasma viral load correlated with lower DAT binding in the caudate and putamen. This inverse relationship between plasma viral burden and DAT availability further support an HIV-mediated neurotoxicity within dopaminergic nerve terminals [95] . A subsequent DAT imaging study assessed the cofounding effects of drug abuse (specifically cocaine) and HIV infection [96] . Although HIVþ patients showed lower DAT binding in the putamen compared with HIV-patients, irrespective of drug abuse, HIVþ patients with a previous history of drug abuse problems had the lowest DAT values in the caudate. These results further support the theory of drug abuse contributing to CNS injury observed in HIVþ patients. Previous cocaine use may increase the release of dopamine, resulting in microglial activation, and possibly increases in viral replication [97] . Apart from the dopaminergic system, only one study has targeted the serotonergic system in HIVþ patients. Using a serotonin transporter ligand, 11 C-DASB, Hammoud et al. [98] showed dysregulated serotonergic transmission in HIVþ patients with depression compared with nondepressed HIVþ patients. This observation may reflect increased density of serotonin, leading to increased clearance of this neurotransmitter from the synapse, which could subsequently lead to depressive symptoms [98] . However, additional longitudinal studies using these compounds and other recently developed ligands are needed in HIVþ patients.
A fourth approach to using PET in neuroHIV has investigated the role of amyloid. Previous pathological studies have shown increases in diffuse plaques in HIVþ patients [99] [100] [101] . With a greying of the HIVþ population, increasing concerns have arisen as to whether older HIVþ patients are at increased risk for developing Alzheimer's disease. PET imaging using the amyloid-binding agent 11 C-labeled Pittsburgh Compound B ( 11 C-PiB) has demonstrated amyloid deposition in preclinical Alzheimer's disease [102] . However, 11 C-PiB studies in HIVþ individuals failed to show increased amyloid accumulation, even in symptomatic (HAND) patients [103, 104] . A more recent study looking at HIVþ patients across a range of ages also did not show significant increases in amyloid typically seen with Alzheimer's disease [105] . Observed differences between HAND and Alzheimer's disease could potentially reflect variances in amyloid metabolism between the two disease entities or the lack of affinity of current amyloid ligands for more diffuse amyloid plaques. Additional studies using more recently developed amyloid agents (e.g., florbetapir) are needed.
CONCLUSION
In conclusion, PET imaging has been used rather limitedly in neuroHIV. However, PET methods have great potential for further characterizing the neuropathophysiological changes associated with HIV, especially in the setting of optimal cART. Evaluation of various neurotransmitter systems apart from the dopaminergic and serotonergic systems might shed more light on selective vulnerability of various neuron subtypes to the virus. Evaluation of the effect of drug abuse on the course of neuroHIV is needed. Most importantly, PET imaging might help finding reliable noninvasive biomarkers of neuronal injury in HIV that could potentially be used in the evaluation of response to treatment and/or neuroprotective measures.
